Mirabegron PCD Pharma Franchise Company
Cafoli Lifecare offers 10 Mirabegron formulations in tablet form, covering extended-release strengths for the urology segment. All products are manufactured at WHO-GMP certified facilities and offered to franchise partners with monopoly rights.
What is Mirabegron?
Mirabegron is a selective beta-3 adrenergic receptor agonist. It relaxes the detrusor muscle during the bladder storage phase, increasing bladder capacity without the anticholinergic side effects of older agents. Further information is available on MedlinePlus.
Therapeutic Applications
Mirabegron is indicated for overactive bladder with symptoms of urgency, increased urinary frequency and urge incontinence. It is prescribed by urologists, uro-gynaecologists, geriatricians and consultant physicians, and is often used in patients who cannot tolerate anticholinergics.
Why Mirabegron is a High-Potential Molecule for Distributors
Overactive bladder is under-treated in India but diagnosis is rising with an ageing population. Mirabegron's better tolerability profile compared with anticholinergics is steadily shifting prescriptions in its favour, and because it is a newer molecule the PCD field is far less crowded than for legacy urology products — good news for margins and for a partner establishing a urology speciality.
Why Choose Cafoli Lifecare
Cafoli provides district-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, competitive net rates and full promotional inputs, with 1000+ franchise partners across India.
References
- MedlinePlus: Mirabegron
- PubChem: Mirabegron
Our formulations of Mirabegron find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: